Daniel Vitt
Directeur Général chez IMMUNIC, INC.
Fortune : 474 865 $ au 30/04/2024
Provenance du réseau au premier degré de Daniel Vitt
Entité | Type d'entité | Industrie | |
---|---|---|---|
22
| Public Company | Biotechnology | 22 |
Public Company | Pharmaceuticals: Major | 20 | |
Julius-Maximilians-Universität Würzburg
16
| College/University | Other Consumer Services | 16 |
Immunic AG
Immunic AG Pharmaceuticals: MajorHealth Technology Immunic AG develops pharmaceuticals in the immunology space. The firm offers immune modulators to block TH17-and TH1-mediated immune and autoimmune responses. The company was founded by Andreas Muhler and Manfred Groppel in April 2016 and is headquartered in Martinsried, Germany.
8
| Subsidiary | Pharmaceuticals: Major | 8 |
Graphique Sociétés connectées au second degré
Relation dans plusieurs entreprises
Sociétés connectées à Daniel Vitt via son réseau personnel
Société | Secteur | Personnes liées | Poste principal |
---|---|---|---|
DSM NV
DSM NV Chemicals: SpecialtyProcess Industries DSM BV engages in the provision of ingredients, expertise, and solutions for plant-based products. It operates through the following segments: Animal Nutrition and Health (ANH); Health, Nutrition, and Care (HNC); Food and Beverage (F and B); and Other. The ANH segment includes developing sustainable animal farming through essential products, performance solutions, and precision services serving the poultry, swine, ruminants, and aquaculture markets. The HNC segment provides health, nutrition, and care solutions for markets such as early life nutrition, dietary supplements, pharma, medical, and personal care. The F and B segment focuses on supporting healthy diets through nutritious, delicious, and sustainable solutions for several market segments including bakery, beverages and brewing, dairy, savory, plant-based alternative proteins, and pet food. The Other segment is involved in corporate activities. The company was founded in 1902 and is headquartered in Heerlen, the Netherlands. | Chemicals: Specialty | Public Communications Contact Public Communications Contact | |
High-Tech Gründerfonds Management GmbH
High-Tech Gründerfonds Management GmbH Investment ManagersFinance High-Tech Gründerfonds Management GmbH (HTGF) is a venture capital firm founded in 2005. The firm is headquartered in Bonn, Germany. | Investment Managers | Private Equity Investor Consultant / Advisor | |
Technische Universität Braunschweig | College/University | Corporate Officer/Principal Undergraduate Degree | |
BRISTOL-MYERS SQUIBB COMPANY | Pharmaceuticals: Major | Corporate Officer/Principal Corporate Officer/Principal | |
MERCK KGAA | Pharmaceuticals: Major | Director/Board Member Corporate Officer/Principal | |
Max Planck Institute of Biochemistry | College/University | Doctorate Degree Doctorate Degree | |
Friedrich-Alexander University of Erlangen-Nuremberg | College/University | Doctorate Degree Corporate Officer/Principal | |
TopoTarget UK Ltd.
TopoTarget UK Ltd. Drugstore ChainsRetail Trade TopoTarget UK Ltd. engages in the discovery and development of drugs and therapies to treat cancer. It develops anti-cancer drugs for molecular mechanisms associated with the cell cycle, chromatin control and DNA damage. The company was founded in 2002 and is headquartered in Oxford, the United Kingdom. | Drugstore Chains | Director/Board Member Corporate Officer/Principal | |
Aicuris Anti-Infective Cures AG
Aicuris Anti-Infective Cures AG Miscellaneous Commercial ServicesCommercial Services Part of Santo Holding (Deutschland) GmbH, Aicuris Anti-Infective Cures AG aims to discover, develop, and deliver innovative, anti-viral drugs to immunocompromised patients aiming to prevent severe condition and life-threatening diseases. The company is based in Wuppertal, Germany. Aicuris has developed a commercial drug as well as pipeline of clinical-stage and pre-clinical anti-viral candidates. Its lead product Prevymis® (letermovir), a first-in-class non-nucleoside cytomegalovirus (CMV) inhibitor, was licensed to MSD and is commercialized for the prevention of human CMV infections in immunocompromised patients who underwent an allogeneic hematopoietic stem cell transplantation or kidney transplantation. Aicuris wholly owned product candidate, Pritelivir, targeting resistant herpes simplex virus (HSV) infections in immunocompromised patients, is in phase 3 clinical development. The German company was founded in 2006 by Helga Rübsamen-Schaeff. Larry G. Edwards has been the CEO of the company since 2023. | Miscellaneous Commercial Services | Founder Chairman | |
Bristol-Myers Squibb GmbH & Co. KGaA
Bristol-Myers Squibb GmbH & Co. KGaA Pharmaceuticals: MajorHealth Technology Part of Bristol Myers Squibb Co., Bristol-Myers Squibb GmbH & Co. KGaA is a German company that manufactures biopharmaceutical medicines. The company is based in Munich, Germany. The CEO of the company is Han Steutel. | Pharmaceuticals: Major | Corporate Officer/Principal Corporate Officer/Principal | |
VIVORYON THERAPEUTICS N.V. | Biotechnology | Director/Board Member Chief Executive Officer | |
AKEBIA THERAPEUTICS, INC. | Pharmaceuticals: Major | Director/Board Member Corporate Officer/Principal | |
Vectura GmbH
Vectura GmbH Medical SpecialtiesHealth Technology Vectura GmbH manufactures and develops pharmaceutical therapies for airways diseases. It offers dry powder formulation technology, device technology, and development capabilities. The company was founded by Gerhard Scheuch in 1997 and is headquartered in Gemünden, Germany. | Medical Specialties | Director/Board Member Corporate Officer/Principal | |
University of Oxford | College/University | Graduate Degree Masters Business Admin | |
KUROS BIOSCIENCES AG | Biotechnology | Director/Board Member Director/Board Member | |
Ventaleon GmbH
Ventaleon GmbH Pharmaceuticals: OtherHealth Technology Ventaleon GmbH is a biotechnology company, which engages in the development of inhaled treatments against viral infections. Its products include LASAG (D,L-lysine acetylsalicylate • glycine), a lysin-salt formulation of well known acetyl salicylic acid. The company was founded by Gerhard Scheuch in 2012 and is headquartered in Gauting, Germany. | Pharmaceuticals: Other | Director/Board Member Chief Executive Officer | |
Sandoz International GmbH
Sandoz International GmbH Pharmaceuticals: GenericHealth Technology Sandoz International GmbH develops and manufactures generic pharmaceuticals. It produces finished dosage forms of such off-patent drugs as diabetes treatment Glucophage, GERD drug Prilosec, and cholesterol. The company was founded in 1996 and is headquartered in Holzkirchen, Austria. | Pharmaceuticals: Generic | Corporate Officer/Principal Corporate Officer/Principal | |
Technische Universität München | College/University | Undergraduate Degree Undergraduate Degree | |
MEDIGENE AG | Biotechnology | Director/Board Member Director/Board Member | |
BAYER AG | Pharmaceuticals: Major | Director of Finance/CFO Corporate Officer/Principal | |
Genzyme Corp.
Genzyme Corp. Medical SpecialtiesHealth Technology Genzyme Corp. engages in development and manufacture of specialty therapeutic, surgical and diagnostic product. It serves in the areas of rare genetic diseases, multiple sclerosis, cardiovascular diseases and endocrinology. The company was founded on June 8, 1981 and is headquartered in Cambridge, MA. | Medical Specialties | Corporate Officer/Principal Corporate Officer/Principal | |
Concentro Management AG
Concentro Management AG Investment ManagersFinance Concentro Management AG is a German company that offers services in corporate development and management. The private company is based in Munich, Germany. The company has offices in Munich, Leipzig, and Stuttgart. The company has supported various insolvency administrators in successful asset transfers and sales of companies. The company has also helped in the age-related succession plan of a shareholder of Ropro Produktions GmbH. Additionally, Concentro Management has increased EBIT and transparency in the group through a comprehensive restructuring program. | Investment Managers | Chairman Director/Board Member | |
AiCuris GmbH & Co. KG
AiCuris GmbH & Co. KG Miscellaneous Commercial ServicesCommercial Services AiCuris GmbH & Co. KG provides research and development services for antiviral and antibacterial agents. The firm develops drugs against viruses such as human cytomegalovirus, herpes simplex virus, hepatitis B virus and human immunodeficiency virus. The company was founded in March 2006 and is headquartered in Wuppertal, Germany. | Miscellaneous Commercial Services | Chief Executive Officer Director/Board Member | |
Minaris Regenerative Medicine GmbH
Minaris Regenerative Medicine GmbH BiotechnologyHealth Technology apceth Biopharma GmbH operates as a contract development & manufacturing organization. The firm specializes in cell-based and gene therapy products (Advanced Therapy Medicinal Products, ATMPs). Its GMP services include quality management, quality control, assay development, process development, cell banking & formulation and project management. The company was founded in 2007 and is headquartered in Munich, Germany. | Biotechnology | Chairman Chief Executive Officer | |
Verinos Pharmaceuticals GmbH | Director/Board Member Director/Board Member | ||
Fund+
Fund+ Investment ManagersFinance Fund+ is an independent Venture Capital firm founded in 2015. The firm is headquartered in Leuven, Belgium. | Investment Managers | Private Equity Investor Private Equity Investor | |
Katholieke Universiteit Leuven | College/University | Graduate Degree Graduate Degree | |
LSP Services Deutschland GmbH | Investment Managers | Private Equity Investor Private Equity Investor | |
Indigo Diabetes NV
Indigo Diabetes NV Medical SpecialtiesHealth Technology Indigo Diabetes NV develops a needle-free glucose sensor by exploiting groundbreaking photonics technology. Its product addresses the need for accurate, low-cost glucose monitoring systems with an optimal user experience. The company was founded by Danae Delbeke on November 17, 2016 and is headquartered in Ghent, Belgium. | Medical Specialties | Director/Board Member Director/Board Member | |
GSK PLC | Pharmaceuticals: Major | Corporate Officer/Principal Corporate Officer/Principal | |
Andera Partners SCA
Andera Partners SCA Investment ManagersFinance Andera Partners SCA (Andera Partners) is a private equity firm founded in 2001 by Pierre-Michel Passy. The firm is headquartered in Paris, France. | Investment Managers | Private Equity Investor Private Equity Investor | |
G2M Cancer Drugs AG
G2M Cancer Drugs AG Miscellaneous Commercial ServicesCommercial Services Part of Valerio Therapeutics SA, G2M Cancer Drugs AG is a German company that researches new anti-cancer therapeutics and develops selected late-stage products. The company is based in Frankfurt am Main, Germany. G2M Cancer Drugs was acquired by Topotarget A/S on March 01, 2005. | Miscellaneous Commercial Services | Director/Board Member Director/Board Member | |
vasopharm GmbH
vasopharm GmbH Pharmaceuticals: MajorHealth Technology vasopharm GmbH operates as a pharmaceutical company. It discovers and develops novel therapeutics for the treatment of cerebro and cardiovascular diseases and their consequences. The firm focuses on therapeutics influencing the bioavailability of nitric oxide. The company was founded by Harald Schmidt and Ulrich Walter in July 1998 and is headquartered in Wuerzburg, Germany. | Pharmaceuticals: Major | Director/Board Member Chief Tech/Sci/R&D Officer | |
Ludwig-Maximilians-Universität München | College/University | Doctorate Degree Graduate Degree | |
Palais Berlin 1 GmbH
Palais Berlin 1 GmbH Real Estate DevelopmentFinance Palais Berlin 1 GmbH is a German company that specializes in the buying and selling of land, buildings, and flats. The private company is based in Munich, Germany. The CEOs of the company are Thomas Maier, Helmut Jeggle, Sebastian Breyer. | Real Estate Development | Chief Executive Officer | |
A&T Grundstück 1 GmbH
A&T Grundstück 1 GmbH Real Estate DevelopmentFinance A & T Grundstück 1 GmbH is a private company based in Munich, Germany. The CEOs of the German company are Thomas Maier, Sebastian Breyer, Helmut Jeggle. The company engages in buying and selling of commercial premises & non-residential buildings. | Real Estate Development | Chief Executive Officer | |
Vogel Business Media GmbH & Co. KG
Vogel Business Media GmbH & Co. KG Publishing: Books/MagazinesConsumer Services Vogel Business Media GmbH & Co. KG provides media and information exchange platforms. It offers a range of print media, online portals, events and customer services in the fields of automation, automobile, electronics, production, logistics, mechanical engineering, design engineering, pharmaceuticals, laboratories, chemicals, bulk material handling, motor trade, information technology, law, business administration, taxation, B2B communications, corporate social responsibility and B2B marketing. The company was founded in 1891 by Carl Gustav Vogel and is headquartered in Wurzburg, Germany. | Publishing: Books/Magazines | Public Communications Contact | |
Pharma Radebeul GmbH
Pharma Radebeul GmbH Finance/Rental/LeasingFinance Part of Jossa Arznei GmbH, Pharma Radebeul GmbH is a company that specializes in rentals and leases of industrial machinery. The company is based in Radebeul, Germany. Michael Riemenschneider has been the CEO of the German company since 2020. | Finance/Rental/Leasing | Chief Executive Officer | |
University of Glasgow | College/University | Graduate Degree | |
Dr. Ernst Strüngmann Foundation gGmbH
Dr. Ernst Strüngmann Foundation gGmbH Miscellaneous Commercial ServicesCommercial Services Dr. Ernst Strüngmann Foundation gGmbH is a biotechnology research and development company based in Munich, Germany. Dr. Ernst Strüngmann Foundation gGmbH engages in research and development on biotechnology. The German company was founded in 2007, and its CEOs are Andreas Strüngmann, Thomas Strüngmann, and Thomas Maier. | Miscellaneous Commercial Services | Chief Executive Officer | |
ATB GmbH
ATB GmbH Financial ConglomeratesFinance ATB GmbH is an investment holding German company founded in 2004. The private company is based in Gera, Germany. | Financial Conglomerates | Chief Executive Officer | |
VP Bank AG (Private Banking)
VP Bank AG (Private Banking) Investment ManagersFinance VP Bank AG (Private Banking) (VP Bank-PB) is the private banking division of VP Bank AG (SWX: VPBN, NASDAQ: VUPPF), an international banking group headquartered in Vaduz, Liechtenstein. The firm was founded by Guido Feger in 1956 as Verwaltungs- und Privat-Bank AG. VP Bank-PB offers tailor-made asset management solutions for private individuals and financial intermediaries. | Investment Managers | Economist | |
TONIES SE | Recreational Products | Director/Board Member | |
A&T Grundstück 2 GmbH
A&T Grundstück 2 GmbH Real Estate DevelopmentFinance A & T Grundstück 2 GmbH is a private company based in Munich, Germany. The CEOs of the German company are Sebastian Breyer, Helmut Jeggle, Thomas Peter Maier. The company buys and sells land, buildings, and apartments. | Real Estate Development | Chief Executive Officer | |
KfW
KfW General GovernmentGovernment KfW provides housing-related loans, grants, and financing services. The firm offers financing for infrastructure projects for municipalities, global funding to regional development agencies and financial institutions, and export and project finance. It also promotes small and medium-sized enterprises, business founders, start-ups, self-employed professionals, and developing and transition countries. The company was founded on November 18, 1948 and is headquartered in Frankfurt am Main, Germany. | General Government | Corporate Officer/Principal |
Statistiques
Internationale
Allemagne | 32 |
Etats-Unis | 6 |
Royaume-Uni | 6 |
Belgique | 4 |
Pays-Bas | 2 |
Sectorielle
Health Technology | 21 |
Finance | 13 |
Consumer Services | 10 |
Commercial Services | 5 |
Process Industries | 2 |
Opérationnelle
Director/Board Member | 216 |
Corporate Officer/Principal | 118 |
Chief Executive Officer | 95 |
Chairman | 47 |
Independent Dir/Board Member | 38 |
Relations les plus connectées
Insiders | |
---|---|
Helmut Jeggle | 47 |
Tamar Howson | 41 |
Jörg Neermann | 34 |
Heiko Roman Michael Fischer | 30 |
Thomas Werner | 25 |
Vincent Ossipow | 22 |
Manfred Rüdiger | 22 |
Jason Loveridge | 20 |
Günter Frankenne | 19 |
Philip Grosse | 18 |
Irina Antonijevic | 17 |
Tamara Favorito | 17 |
Clemens M. Doppler | 17 |
Barclay Phillips | 16 |
Helga Rübsamen-Schaeff | 16 |
- Bourse
- Insiders
- Daniel Vitt
- Connexions Sociétés